Regulation of sphingosine kinase in hematological malignancies and other cancers

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 799-809

  Pitson, Stuart M ^a,b   Powell, Jason A ^a,b   Bonder, Claudine S ^a,b  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cancer; Ceramide; Chronic myeloid leukemia; Hematological malignacy; Sphingosine; Sphingosine 1 phosphate; Sphingosine kinase

Indexed keywords

2 (4 HYDROXYANILINO) 4 (4 CHLOROPHENYL)THIAZOLE; 3 (4 CHLOROPHENYL)ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL)AMIDE; ABC 294640; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAMPTOTHECIN; CELL SURFACE RECEPTOR; CERAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; IDRONOXIL; IMATINIB; N,N DIMETHYLSPHINGOSINE; RESVERATROL; SPHINGOSINE; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; TAMOXIFEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; ENZYME REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; OVARY CANCER; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 80054082629     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797655078     Document Type: Article

References (178)

1. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
2. Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S. Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets, 2008, 9(8), 662-673.
3. Cuvillier, O.; Ader, I.; Bouquerel, P.; Brizuela, L.; Malavaud, B.; Mazerolles, C.; Rischmann, P. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr. Mol. Pharmacol., 2010, 3(2), 53-65.
4. Pyne, N.J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10(7), 489-503.
5. Hannun, Y.A.; Obeid, L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol., 2008, 9(2), 139-150.
6. Pebay, A.; Bonder, C.S.; Pitson, S.M. Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat., 2007, 84(3-4), 83-97.
7. Saddoughi, S.A.; Song, P.; Ogretmen, B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem., 2008, 49, 413-440.
8. Sun, W.Y.; Pitson, S.M.; Bonder, C.S. Tumor necrosis factorinduced neutrophil adhesion occurs via sphingosine kinase-1- dependent activation of endothelial {alpha}5{beta}1 integrin. Am. J. Pathol., 2010, 177(1), 436-446.
9. Xia, P.; Gamble, J.R.; Rye, K.A.; Wang, L.; Hii, C.S.; Cockerill, P.; Khew-Goodall, Y.; Bert, A.G.; Barter, P.J.; Vadas, M.A. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl. Acad. Sci. USA, 1998, 95(24), 14196-14201.
10. Matloubian, M.; Lo, C.G.; Cinamon, G.; Lesneski, M.J.; Xu, Y.; Brinkmann, V.; Allende, M.L.; Proia, R.L.; Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004, 427(6972), 355-360.
11. Allende, M.L.; Dreier, J.L.; Mandala, S.; Proia, R.L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J. Biol. Chem., 2004, 279(15), 15396-15401.
12. Oskeritzian, C.A.; Alvarez, S.E.; Hait, N.C.; Price, M.M.; Milstien, S.; Spiegel, S. Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions. Blood, 2008, 111(8), 4193-4200.
13. Idzko, M.; Panther, E.; Corinti, S.; Morelli, A.; Ferrari, D.; Herouy, Y.; Dichmann, S.; Mockenhaupt, M.; Gebicke-Haerter, P.; Di Virgilio, F.; Girolomoni, G.; Norgauer, J. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J., 2002, 16(6), 625-627.
14. Hughes, J.E.; Srinivasan, S.; Lynch, K.R.; Proia, R.L.; Ferdek, P.; Hedrick, C.C. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ. Res., 2008, 102(8), 950-958.
15. Dorsam, G.; Graeler, M.H.; Seroogy, C.; Kong, Y.; Voice, J.K.; Goetzl, E.J. Transduction of multiple effects of sphingosine 1- phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. J. Immunol., 2003, 171(7), 3500-3507.
16. Pitson, S.M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci., 2011, 36(2), 97-107.
17. Chalfant, C.E.; Szulc, Z.; Roddy, P.; Bielawska, A.; Hannun, Y.A. The structural requirements for ceramide activation of serinethreonine protein phosphatases. J Lipid Res., 2004, 45(3), 496-506.
18. Muller, G.; Ayoub, M.; Storz, P.; Rennecke, J.; Fabbro, D.; Pfizenmaier, K. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J., 1995, 14(9), 1961-1969.
19. Zhang, Y.; Yao, B.; Delikat, S.; Bayoumy, S.; Lin, X.H.; Basu, S.; McGinley, M.; Chan-Hui, P.Y.; Lichenstein, H.; Kolesnick, R. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell, 1997, 89(1), 63-72.
20. Heinrich, M.; Neumeyer, J.; Jakob, M.; Hallas, C.; Tchikov, V.; Winoto-Morbach, S.; Wickel, M.; Schneider-Brachert, W.; Trauzold, A.; Hethke, A.; Schutze, S. Cathepsin D links TNFinduced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ., 2004, 11(5), 550-563.
21. Woodcock, J.M.; Ma, Y.; Coolen, C.; Pham, D.; Jones, C.; Lopez, A.F.; Pitson, S.M. Sphingosine and FTY720 directly bind prosurvival 14-3-3 proteins to regulate their function. Cell Signal, 2010, 22(9), 1291-1299.
22. Smith, E.R.; Merrill, A.H.; Obeid, L.M.; Hannun, Y.A. Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol., 2000, 312, 361-373.
23. Woodcock, J. Sphingosine and ceramide signalling in apoptosis. IUBMB Life, 2006, 58(8), 462-466.
24. Habrukowich, C.; Han, D.K.; Le, A.; Rezaul, K.; Pan, W.; Ghosh, M.; Li, Z.; Dodge-Kafka, K.; Jiang, X.; Bittman, R.; Hla, T. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J. Biol. Chem., 2010, 285(35), 26825-26831.
25. Rosen, H.; Gonzalez-Cabrera, P.J.; Sanna, M.G.; Brown, S. Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem., 2009, 78, 743-768.
26. Skoura, A.; Hla, T. Lysophospholipid receptors in vertebrate development, physiology, and pathology. J. Lipid Res., 2009, 50 Suppl, S293-298.
27. Maceyka, M.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J. Lipid Res., 2009, 50 Suppl, S272-276.
28. Hait, N.C.; Allegood, J.; Maceyka, M.; Strub, G.M.; Harikumar, K.B.; Singh, S.K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; Spiegel, S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 2009, 325(5945), 1254-1257.
29. Alvarez, S.E.; Harikumar, K.B.; Hait, N.C.; Allegood, J.; Strub, G.M.; Kim, E.Y.; Maceyka, M.; Jiang, H.; Luo, C.; Kordula, T.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature, 2010, 465(7301), 1084-1088.
30. Strub, G.M.; Paillard, M.; Liang, J.; Gomez, L.; Allegood, J.C.; Hait, N.C.; Maceyka, M.; Price, M.M.; Chen, Q.; Simpson, D.C.; Kordula, T.; Milstien, S.; Lesnefsky, E.J.; Spiegel, S. Sphingosine- 1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J., 2011, 25(2), 600-612.
31. Pitman, M.R.; Pitson, S.M. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr. Cancer Drug Targets, 2010, 10(4), 354-367.
32. Leclercq, T.M.; Pitson, S.M. Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. IUBMB Life, 2006, 58(8), 467-472.
33. Liu, H.; Sugiura, M.; Nava, V.E.; Edsall, L.C.; Kono, K.; Poulton, S.; Milstien, S.; Kohama, T.; Spiegel, S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem., 2000, 275(26), 19513-19520.
34. Billich, A.; Bornancin, F.; Devay, P.; Mechtcheriakova, D.; Urtz, N.; Baumruker, T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem., 2003, 278(48), 47408-47415.
35. Paugh, S.W.; Payne, S.G.; Barbour, S.E.; Milstien, S.; Spiegel, S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett., 2003, 554(1-2), 189-193.
36. Allende, M.L.; Sasaki, T.; Kawai, H.; Olivera, A.; Mi, Y.; van Echten-Deckert, G.; Hajdu, R.; Rosenbach, M.; Keohane, C.A.; Mandala, S.; Spiegel, S.; Proia, R.L. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem., 2004, 279(50), 52487-52492.
37. Mizugishi, K.; Yamashita, T.; Olivera, A.; Miller, G.F.; Spiegel, S.; Proia, R.L. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol., 2005, 25(24), 11113-11121.
38. Kharel, Y.; Lee, S.; Snyder, A.H.; Sheasley-O'neill S. L.; Morris, M.A.; Setiady, Y.; Zhu, R.; Zigler, M.A.; Burcin, T.L.; Ley, K.; Tung, K.S.; Engelhard, V.H.; Macdonald, T.L.; Pearson-White, S.; Lynch, K.R. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem., 2005, 280(44), 36865-36872.
39. Zemann, B.; Kinzel, B.; Muller, M.; Reuschel, R.; Mechtcheriakova, D.; Urtz, N.; Bornancin, F.; Baumruker, T.; Billich, A. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood, 2006, 107(4), 1454-1458.
40. Lai, W.Q.; Irwan, A.W.; Goh, H.H.; Melendez, A.J.; McInnes, I.B.; Leung, B.P. Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J. Immunol., 2009, 183(3), 2097-2103.
41. Jo, S.K.; Bajwa, A.; Ye, H.; Vergis, A.L.; Awad, A.S.; Kharel, Y.; Lynch, K.R.; Okusa, M.D. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int., 2009, 75(2), 167-175.
42. Wadgaonkar, R.; Patel, V.; Grinkina, N.; Romano, C.; Liu, J.; Zhao, Y.; Sammani, S.; Garcia, J.G.; Natarajan, V. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am. J. Physiol. Lung Cell Mol. Physiol., 2009, 296(4), L603-613.
43. Igarashi, N.; Okada, T.; Hayashi, S.; Fujita, T.; Jahangeer, S.; Nakamura, S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem., 2003, 278(47), 46832-46839.
44. Maceyka, M.; Sankala, H.; Hait, N.C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.S.; Merrill, A.H., Jr.; Milstien, S.; Spiegel, S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol. Chem., 2005, 280(44), 37118-37129.
45. Hofmann, L.P.; Ren, S.; Schwalm, S.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Bio.l Chem., 2008, 389(11), 1399-1407.
46. Liu, H.; Toman, R.E.; Goparaju, S.K.; Maceyka, M.; Nava, V.E.; Sankala, H.; Payne, S.G.; Bektas, M.; Ishii, I.; Chun, J.; Milstien, S.; Spiegel, S. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem., 2003, 278(41), 40330-40336.
47. Okada, T.; Ding, G.; Sonoda, H.; Kajimoto, T.; Haga, Y.; Khosrowbeygi, A.; Gao, S.; Miwa, N.; Jahangeer, S.; Nakamura, S. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J. Biol. Chem., 2005, 280(43), 36318-36325.
48. Van Brocklyn, J.R.; Jackson, C.A.; Pearl, D.K.; Kotur, M.S.; Snyder, P.J.; Prior, T.W. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J. Neuropathol. Exp. Neurol., 2005, 64(8), 695-705.
49. Nemoto, S.; Nakamura, M.; Osawa, Y.; Kono, S.; Itoh, Y.; Okano, Y.; Murate, T.; Hara, A.; Ueda, H.; Nozawa, Y.; Banno, Y. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J. Biol. Chem., 2009, 284(16), 10422-10432.
50. Sankala, H.M.; Hait, N.C.; Paugh, S.W.; Shida, D.; Lepine, S.; Elmore, L.W.; Dent, P.; Milstien, S.; Spiegel, S. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res., 2007, 67(21), 10466-10474.
51. Schnitzer, S.E.; Weigert, A.; Zhou, J.; Brune, B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1- phosphate-mediated chemoresistance in A549 lung cancer cells. Mol. Cancer Res., 2009, 7(3), 393-401.
52. Venkataraman, K.; Thangada, S.; Michaud, J.; Oo, M.L.; Ai, Y.; Lee, Y.M.; Wu, M.; Parikh, N.S.; Khan, F.; Proia, R.L.; Hla, T. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem. J., 2006, 397(3), 461-471.
53. Olivera, A.; Kohama, T.; Edsall, L.; Nava, V.; Cuvillier, O.; Poulton, S.; Spiegel, S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol., 1999, 147(3), 545-558.
54. Edsall, L.C.; Cuvillier, O.; Twitty, S.; Spiegel, S.; Milstien, S. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem., 2001, 76(5), 1573-1584.
55. Xia, P.; Gamble, J.R.; Wang, L.; Pitson, S.M.; Moretti, P.A.; Wattenberg, B.W.; D'Andrea, R.J.; Vadas, M.A. An oncogenic role of sphingosine kinase. Curr. Biol., 2000, 10(23), 1527-1530.
56. Gamble, J.R.; Sun, W.Y.; Li, X.; Hahn, C.N.; Pitson, S.M.; Vadas, M.A.; Bonder, C.S. Sphingosine kinase-1 associates with integrin {alpha}V{beta}3 to mediate endothelial cell survival. Am. J. Pathol., 2009, 175(5), 2217-2225.
57. Sukocheva, O.A.; Wang, L.; Albanese, N.; Pitson, S.M.; Vadas, M.A.; Xia, P. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol. Endocrinol., 2003, 17(10), 2002-2012.
58. Nava, V.E.; Hobson, J.P.; Murthy, S.; Milstien, S.; Spiegel, S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell Res., 2002, 281(1), 115-127.
59. Dayon, A.; Brizuela, L.; Martin, C.; Mazerolles, C.; Pirot, N.; Doumerc, N.; Nogueira, L.; Golzio, M.; Teissie, J.; Serre, G.; Rischmann, P.; Malavaud, B.; Cuvillier, O. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One, 2009, 4(11), e8048.
60. Kohno, M.; Momoi, M.; Oo, M.L.; Paik, J.H.; Lee, Y.M.; Venkataraman, K.; Ai, Y.; Ristimaki, A.P.; Fyrst, H.; Sano, H.; Rosenberg, D.; Saba, J.D.; Proia, R.L.; Hla, T. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol. Cell Biol., 2006, 26(19), 7211-7223.
61. Kawamori, T.; Kaneshiro, T.; Okumura, M.; Maalouf, S.; Uflacker, A.; Bielawski, J.; Hannun, Y.A.; Obeid, L.M. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J., 2009, 23(2), 405-414.
62. French, K.J.; Schrecengost, R.S.; Lee, B.D.; Zhuang, Y.; Smith, S.N.; Eberly, J.L.; Yun, J.K.; Smith, C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63(18), 5962-5969.
63. Johnson, K.R.; Johnson, K.Y.; Crellin, H.G.; Ogretmen, B.; Boylan, A.M.; Harley, R.A.; Obeid, L.M. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J. Histochem. Cytochem., 2005, 53(9), 1159-1166.
64. Kawamori, T.; Osta, W.; Johnson, K.R.; Pettus, B.J.; Bielawski, J.; Tanaka, T.; Wargovich, M.J.; Reddy, B.S.; Hannun, Y.A.; Obeid, L.M.; Zhou, D. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J, 2006, 20(2), 386-388.
65. Li, J.; Guan, H.Y.; Gong, L.Y.; Song, L.B.; Zhang, N.; Wu, J.; Yuan, J.; Zheng, Y.J.; Huang, Z.S.; Li, M. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin. Cancer Res., 2008, 14(21), 6996-7003.
66. Guillermet-Guibert, J.; Davenne, L.; Pchejetski, D.; Saint-Laurent, N.; Brizuela, L.; Guilbeau-Frugier, C.; Delisle, M.B.; Cuvillier, O.; Susini, C.; Bousquet, C. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol. Cancer Ther., 2009, 8(4), 809-820.
67. Li, W.; Yu, C.P.; Xia, J.T.; Zhang, L.; Weng, G.X.; Zheng, H.Q.; Kong, Q.L.; Hu, L.J.; Zeng, M.S.; Zeng, Y.X.; Li, M.; Li, J.; Song, L.B. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res., 2009, 15(4), 1393-1399.
68. Liu, G.; Zheng, H.; Zhang, Z.; Wu, Z.; Xiong, H.; Li, J.; Song, L. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer, 2010, 10, 495.
69. Malavaud, B.; Pchejetski, D.; Mazerolles, C.; de Paiva, G.R.; Calvet, C.; Doumerc, N.; Pitson, S.; Rischmann, P.; Cuvillier, O. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur. J. Cancer, 2010, 46(18), 3417-3424.
70. Ruckhaberle, E.; Rody, A.; Engels, K.; Gaetje, R.; von Minckwitz, G.; Schiffmann, S.; Grosch, S.; Geisslinger, G.; Holtrich, U.; Karn, T.; Kaufmann, M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat., 2008, 112(1), 41-52.
71. Watson, C.; Long, J.S.; Orange, C.; Tannahill, C.L.; Mallon, E.; McGlynn, L.M.; Pyne, S.; Pyne, N.J.; Edwards, J. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptorpositive breast cancer patients. Am. J. Pathol., 2010, 177(5), 2205-2215.
72. Facchinetti, M.M.; Gandini, N.A.; Fermento, M.E.; Sterin-Speziale, N.B.; Ji, Y.; Patel, V.; Gutkind, J.S.; Rivadulla, M.G.; Curino, A.C. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs, 2010, 192(5), 314-324.
73. Sinha, U.K.; Schorn, V.J.; Hochstim, C.; Chinn, S.B.; Zhu, S.; Masood, R. Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. Head Neck, 2011, 33(2), 178-188.
74. French, K.J.; Upson, J.J.; Keller, S.N.; Zhuang, Y.; Yun, J.K.; Smith, C.D. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther., 2006, 318(2), 596-603.
75. Endo, K.; Igarashi, Y.; Nisar, M.; Zhou, Q.H.; Hakomori, S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res., 1991, 51(6), 1613-1618.
76. Kapitonov, D.; Allegood, J.C.; Mitchell, C.; Hait, N.C.; Almenara, J.A.; Adams, J.K.; Zipkin, R.E.; Dent, P.; Kordula, T.; Milstien, S.; Spiegel, S. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res., 2009, 69(17), 6915-6923.
77. Dickson, M.A.; Carvajal, R.D.; Merrill, A.H., Jr.; Gonen, M.; Cane, L.M.; Schwartz, G.K. A phase I clinical trial of safingol in combination with Cisplatin in advanced solid tumors. Clin. Cancer Res., 2011, 17(8), 2484-2492.
78. Pchejetski, D.; Doumerc, N.; Golzio, M.; Naymark, M.; Teissie, J.; Kohama, T.; Waxman, J.; Malavaud, B.; Cuvillier, O. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther., 2008, 7(7), 1836-1845.
79. Song, L.; Xiong, H.; Li, M.; Liao, W.T.; Wang, L.; Wu, J. Sphingosine kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-{kappa}B Pathway in Human Nonsmall Cell Lung Cancer. Clin. Cancer Res., 2011.
80. Huwiler, A.; Kotelevets, N.; Xin, C.; Pastukhov, O.; Pfeilschifter, J.; Zangemeister-Wittke, U. Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br. J. Pharmacol., 2011, 162(2), 532-543.
81. Sukocheva, O.; Wang, L.; Verrier, E.; Vadas, M.A.; Xia, P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology, 2009, 150(10), 4484-4492.
82. Liu, Y.; Wada, R.; Yamashita, T.; Mi, Y.; Deng, C.X.; Hobson, J.P.; Rosenfeldt, H.M.; Nava, V.E.; Chae, S.S.; Lee, M.J.; Liu, C.H.; Hla, T.; Spiegel, S.; Proia, R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest., 2000, 106(8), 951-961.
83. Lee, O.H.; Kim, Y.M.; Lee, Y.M.; Moon, E.J.; Lee, D.J.; Kim, J.H.; Kim, K.W.; Kwon, Y.G. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 1999, 264(3), 743-750.
84. Anelli, V.; Gault, C.R.; Snider, A.J.; Obeid, L.M. Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. FASEB J., 2010, 24(8), 2727-2738.
85. Visentin, B.; Vekich, J.A.; Sibbald, B.J.; Cavalli, A.L.; Moreno, K.M.; Matteo, R.G.; Garland, W.A.; Lu, Y.; Yu, S.; Hall, H.S.; Kundra, V.; Mills, G.B.; Sabbadini, R.A. Validation of an antisphingosine- 1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 2006, 9(3), 225-238.
86. Tengood, J.E.; Kovach, K.M.; Vescovi, P.E.; Russell, A.J.; Little, S.R. Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis. Biomaterials, 2010, 31(30), 7805-7812.
87. Bonder, C.S.; Sun, W.Y.; Matthews, T.; Cassano, C.; Li, X.; Ramshaw, H.S.; Pitson, S.M.; Lopez, A.F.; Coates, P.T.; Proia, R.L.; Vadas, M.A.; Gamble, J.R. Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation. Blood, 2009, 113(9), 2108-2117.
88. Weigert, A.; Schiffmann, S.; Sekar, D.; Ley, S.; Menrad, H.; Werno, C.; Grosch, S.; Geisslinger, G.; Brune, B. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int. J. Cancer, 2009, 125(9), 2114-2121.
89. French, K.J.; Zhuang, Y.; Maines, L.W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J.J.; Green, C.L.; Keller, S.N.; Smith, C.D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp Ther., 2010, 333(1), 129-139.
90. Beljanski, V.; Knaak, C.; Smith, C.D. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J. Pharmacol. Exp Ther., 2010, 333(2), 454-464.
91. Beljanski, V.; Knaak, C.; Zhuang, Y.; Smith, C.D. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest. New Drugs, 2010.
92. Chumanevich, A.A.; Poudyal, D.; Cui, X.; Davis, T.; Wood, P.A.; Smith, C.D.; Hofseth, L.J. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis, 2010, 31(10), 1787-1793.
93. Antoon, J.W.; White, M.D.; Slaughter, E.M.; Davis, J.L.; Khalili, H.S.; Elliott, S.; Smith, C.D.; Burow, M.E.; Beckman, B.S. Targeting NF-kB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol. Ther., 2011, 11(7).
94. Beljanski, V.; Lewis, C.S.; Smith, C.D. Antitumor activity of Sphingosine Kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol. Ther., 2011, 11(5).
95. Deininger, M.W.; Goldman, J.M.; Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood, 2000, 96(10), 3343-3356.
96. Lugo, T.G.; Pendergast, A.M.; Muller, A.J.; Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 1990, 247(4946), 1079-1082.
97. Sobue, S.; Nemoto, S.; Murakami, M.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Nakamura, M.; Ito, Y.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int. J. Hematol., 2008, 87(3), 266-275.
98. Li, Q.F.; Huang, W.R.; Duan, H.F.; Wang, H.; Wu, C.T.; Wang, L.S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene, 2007, 26(57), 7904-7908.
99. Bonhoure, E.; Lauret, A.; Barnes, D.J.; Martin, C.; Malavaud, B.; Kohama, T.; Melo, J.V.; Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia, 2008, 22(5), 971-979.
100. Hochhaus, A.; O'Brien, S.G.; Guilhot, F.; Druker, B.J.; Branford, S.; Foroni, L.; Goldman, J.M.; Muller, M.C.; Radich, J.P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T.P.; Larson, R.A. Sixyear follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 2009, 23(6), 1054-1061.
101. Bixby, D.; Talpaz, M. Seeking the causes and solutions to imatinibresistance in chronic myeloid leukemia. Leukemia, 2011, 25(1), 7-22.
102. Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1- phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282(15), 10922-10934.
103. Ricci, C.; Onida, F.; Servida, F.; Radaelli, F.; Saporiti, G.; Todoerti, K.; Deliliers, G.L.; Ghidoni, R. In vitro anti-leukaemia activity of sphingosine kinase inhibitor. Br. J. Haematol., 2009, 144(3), 350-357.
104. Quintas-Cardama, A.; Kantarjian, H.; Cortes, J. Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat. Rev. Clin. Oncol., 2009, 6(9), 535-543.
105. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20(1), 95-102.
106. Paugh, S.W.; Paugh, B.S.; Rahmani, M.; Kapitonov, D.; Almenara, J.A.; Kordula, T.; Milstien, S.; Adams, J.K.; Zipkin, R.E.; Grant, S.; Spiegel, S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112(4), 1382-1391.
107. Le Scolan, E.; Pchejetski, D.; Banno, Y.; Denis, N.; Mayeux, P.; Vainchenker, W.; Levade, T.; Moreau-Gachelin, F. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood, 2005, 106(5), 1808-1816.
108. Bayerl, M.G.; Bruggeman, R.D.; Conroy, E.J.; Hengst, J.A.; King, T.S.; Jimenez, M.; Claxton, D.F.; Yun, J.K. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk. Lymphoma, 2008, 49(5), 948-954.
109. Li, Q.F.; Wu, C.T.; Duan, H.F.; Sun, H.Y.; Wang, H.; Lu, Z.Z.; Zhang, Q.W.; Liu, H.J.; Wang, L.S. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br. J. Haematol., 2007, 138(5), 632-639.
110. Li, Q.F.; Zhu, H.Y.; Yang, Y.F.; Liu, J.; Xiao, F.J.; Zhang, Q.W.; Wu, C.T.; Wang, H.; Wang, L.S. Prokineticin-1/endocrine glandderived vascular endothelial growth factor is a survival factor for human multiple myeloma cells. Leuk. Lymphoma, 2010, 51(10), 1902-1912.
111. Doll, F.; Pfeilschifter, J.; Huwiler, A. Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration. Endocr Relat Cancer, 2007, 14(2), 325-335.
112. Doll, F.; Pfeilschifter, J.; Huwiler, A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim. Biophys. Acta, 2005, 1738(1-3), 72-81.
113. Kleuser, B.; Maceyka, M.; Milstien, S.; Spiegel, S. Stimulation of nuclear sphingosine kinase activity by platelet-derived growth factor. FEBS Lett., 2001, 503(1), 85-90.
114. Sobue, S.; Hagiwara, K.; Banno, Y.; Tamiya-Koizumi, K.; Suzuki, M.; Takagi, A.; Kojima, T.; Asano, H.; Nozawa, Y.; Murate, T. Transcription factor specificity protein 1 (Sp1) is the main regulator of nerve growth factor-induced sphingosine kinase 1 gene expression of the rat pheochromocytoma cell line, PC12. J. Neurochem., 2005, 95(4), 940-949.
115. Nakade, Y.; Banno, Y.; K, T.K.; Hagiwara, K.; Sobue, S.; Koda, M.; Suzuki, M.; Kojima, T.; Takagi, A.; Asano, H.; Nozawa, Y.; Murate, T. Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim. Biophys. Acta, 2003, 1635(2-3), 104-116.
116. Huwiler, A.; Doll, F.; Ren, S.; Klawitter, S.; Greening, A.; Romer, I.; Bubnova, S.; Reinsberg, L.; Pfeilschifter, J. Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism. Biochim. Biophys. Acta, 2006, 1761(3), 367-376.
117. Klawitter, S.; Hofmann, L.P.; Pfeilschifter, J.; Huwiler, A. Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. Br. J. Pharmacol., 2007, 150(3), 271-280.
118. Paugh, B.S.; Bryan, L.; Paugh, S.W.; Wilczynska, K.M.; Alvarez, S.M.; Singh, S.K.; Kapitonov, D.; Rokita, H.; Wright, S.; Griswold-Prenner, I.; Milstien, S.; Spiegel, S.; Kordula, T. Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J. Biol. Chem., 2009, 284(6), 3408-3417.
119. Manggau, M.; Kim, D.S.; Ruwisch, L.; Vogler, R.; Korting, H.C.; Schafer-Korting, M.; Kleuser, B. 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J. Invest. Dermatol., 2001, 117(5), 1241-1249.
120. Buehrer, B.M.; Bardes, E.S.; Bell, R.M. Protein kinase Cdependent regulation of human erythroleukemia (HEL) cell sphingosine kinase activity. Biochim. Biophys. Acta, 1996, 1303(3), 233-242.
121. Donati, C.; Cencetti, F.; De Palma, C.; Rapizzi, E.; Brunelli, S.; Cossu, G.; Clementi, E.; Bruni, P. TGFbeta protects mesoangioblasts from apoptosis via sphingosine kinase-1 regulation. Cell Signal, 2009, 21(2), 228-236.
122. Murakami, M.; Ichihara, M.; Sobue, S.; Kikuchi, R.; Ito, H.; Kimura, A.; Iwasaki, T.; Takagi, A.; Kojima, T.; Takahashi, M.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T. RET signalinginduced SPHK1 gene expression plays a role in both GDNFinduced differentiation and MEN2-type oncogenesis. J. Neurochem., 2007, 102(5), 1585-1594.
123. Schwalm, S.; Doll, F.; Romer, I.; Bubnova, S.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem. Biophys. Res. Commun., 2008, 368(4), 1020-1025.
124. Ahmad, M.; Long, J.S.; Pyne, N.J.; Pyne, S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins Other Lipid Mediat., 2006, 79(3-4), 278-286.
125. Anelli, V.; Gault, C.R.; Cheng, A.B.; Obeid, L.M. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J. Biol. Chem., 2008, 283(6), 3365-3375.
126. Boyle, R.G.; Travers, S. Hypoxia: targeting the tumour. Anticancer Agents Med. Chem., 2006, 6(4), 281-286.
127. Long, J.S.; Edwards, J.; Watson, C.; Tovey, S.; Mair, K.M.; Schiff, R.; Natarajan, V.; Pyne, N.J.; Pyne, S. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol. Cell Biol., 2010, 30(15), 3827-3841.
128. Sobue, S.; Murakami, M.; Banno, Y.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Suzuki, M.; Nozawa, Y.; Murate, T. v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene, 2008, 27(46), 6023-6033.
129. Li, Q.F.; Yan, J.; Zhang, K.; Yang, Y.F.; Xiao, F.J.; Wu, C.T.; Wang, H.; Wang, L.S. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl(+) cells sensitive and resistant to STI571 through down-regulation Mcl-1. Biochem. Biophys. Res. Commun., 2011, 405(1), 31-36.
130. Cakir, Z.; Saydam, G.; Sahin, F.; Baran, Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J. Cancer Res. Clin. Oncol., 2010.
131. Brizuela, L.; Dayon, A.; Doumerc, N.; Ader, I.; Golzio, M.; Izard, J.C.; Hara, Y.; Malavaud, B.; Cuvillier, O. The sphingosine kinase- 1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J., 2010, 24(10), 3882-3894.
132. Taha, T.A.; Osta, W.; Kozhaya, L.; Bielawski, J.; Johnson, K.R.; Gillanders, W.E.; Dbaibo, G.S.; Hannun, Y.A.; Obeid, L.M. Downregulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J. Biol. Chem., 2004, 279(19), 20546-20554.
133. Pchejetski, D.; Golzio, M.; Bonhoure, E.; Calvet, C.; Doumerc, N.; Garcia, V.; Mazerolles, C.; Rischmann, P.; Teissie, J.; Malavaud, B.; Cuvillier, O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res., 2005, 65(24), 11667-11675.
134. Taha, T.A.; Kitatani, K.; Bielawski, J.; Cho, W.; Hannun, Y.A.; Obeid, L.M. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J. Biol. Chem., 2005, 280(17), 17196-17202.
135. Taha, T.A.; El-Alwani, M.; Hannun, Y.A.; Obeid, L.M. Sphingosine kinase-1 is cleaved by cathepsin B in vitro: identification of the initial cleavage sites for the protease. FEBS Lett., 2006, 580(26), 6047-6054.
136. Loveridge, C.; Tonelli, F.; Leclercq, T.; Lim, K.G.; Long, J.S.; Berdyshev, E.; Tate, R.J.; Natarajan, V.; Pitson, S.M.; Pyne, N.J.; Pyne, S. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)- 4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem., 2010, 285(50), 38841-38852.
137. Ren, S.; Xin, C.; Pfeilschifter, J.; Huwiler, A. A novel mode of action of the putative sphingosine kinase inhibitor 2-(phydroxyanilino)- 4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol. Biochem., 2010, 26(1), 97-104.
138. Tonelli, F.; Lim, K.G.; Loveridge, C.; Long, J.; Pitson, S.M.; Tigyi, G.; Bittman, R.; Pyne, S.; Pyne, N.J. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal, 2010, 22(10), 1536-1542.
139. Roberts, K.G.; Smith, A.M.; McDougall, F.; Carpenter, H.; Horan, M.; Neviani, P.; Powell, J.A.; Thomas, D.; Guthridge, M.A.; Perrotti, D.; Sim, A.T.; Ashman, L.K.; Verrills, N.M. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res., 2010, 70(13), 5438-5447.
140. Neviani, P.; Santhanam, R.; Oaks, J.J.; Eiring, A.M.; Notari, M.; Blaser, B.W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti- Passerini, C.; Druker, B.J.; Cortes, J.; Marcucci, G.; Chen, C.S.; Verrills, N.M.; Roy, D.C.; Caligiuri, M.A.; Bloomfield, C.D.; Byrd, J.C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117(9), 2408-2421.
141. Pitson, S.M.; Moretti, P.A.; Zebol, J.R.; Xia, P.; Gamble, J.R.; Vadas, M.A.; D'Andrea, R.J.; Wattenberg, B.W. Expression of a catalytically inactive sphingosine kinase mutant blocks agonistinduced sphingosine kinase activation. A dominant-negative sphingosine kinase. J. Biol. Chem., 2000, 275(43), 33945-33950.
142. Wattenberg, B.W.; Pitson, S.M.; Raben, D.M. The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J. Lipid Res., 2006, 47(6), 1128-1139.
143. Pitson, S.M.; Moretti, P.A.; Zebol, J.R.; Lynn, H.E.; Xia, P.; Vadas, M.A.; Wattenberg, B.W. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J., 2003, 22(20), 5491-5500.
144. Pitson, S.M.; Xia, P.; Leclercq, T.M.; Moretti, P.A.; Zebol, J.R.; Lynn, H.E.; Wattenberg, B.W.; Vadas, M.A. Phosphorylationdependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med., 2005, 201(1), 49-54.
145. Jarman, K.E.; Moretti, P.A.; Zebol, J.R.; Pitson, S.M. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J. Biol. Chem., 2010, 285(1), 483-492.
146. Stahelin, R.V.; Hwang, J.H.; Kim, J.H.; Park, Z.Y.; Johnson, K.R.; Obeid, L.M.; Cho, W. The mechanism of membrane targeting of human sphingosine kinase 1. J. Biol. Chem., 2005, 280(52), 43030-43038.
147. Delon, C.; Manifava, M.; Wood, E.; Thompson, D.; Krugmann, S.; Pyne, S.; Ktistakis, N.T. Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. J. Biol. Chem., 2004, 279(43), 44763-44774.
148. Maceyka, M.; Alvarez, S.E.; Milstien, S.; Spiegel, S. Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol. Cell Biol., 2008, 28(18), 5687-5697.
149. Barr, R.K.; Lynn, H.E.; Moretti, P.A.; Khew-Goodall, Y.; Pitson, S.M. Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J. Biol. Chem., 2008, 283(50), 34994-35002.
150. Pitman, M.R.; Barr, R.K.; Gliddon, B.L.; Magarey, A.M.; Moretti, P.A.; Pitson, S.M. A critical role for the protein phosphatase 2A B'alpha regulatory subunit in dephosphorylation of sphingosine kinase 1. Int. J. Biochem. Cell Biol., 2011, 43(3), 342-347.
151. Arnold, H.K.; Sears, R.C. A tumor suppressor role for PP2AB56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev., 2008, 27(2), 147-158.
152. Kim, E.K.; Choi, E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta, 2010, 1802(4), 396-405.
153. Alvarado, Y.; Giles, F.J. Ras as a therapeutic target in hematologic malignancies. Expert Opin. Emerg. Drugs, 2007, 12(2), 271-284.
154. Melendez, A.J.; Khaw, A.K. Dichotomy of Ca2+ signals triggered by different phospholipid pathways in antigen stimulation of human mast cells. J. Biol. Chem., 2002, 277(19), 17255-17262.
155. Duan, H.F.; Wu, C.T.; Lu, Y.; Wang, H.; Liu, H.J.; Zhang, Q.W.; Jia, X.X.; Lu, Z.Z.; Wang, L.S. Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells. Exp. Cell Res., 2004, 298(2), 593-601.
156. Olivera, A.; Rosenthal, J.; Spiegel, S. Effect of acidic phospholipids on sphingosine kinase. J. Cell Biochem., 1996, 60(4), 529-537.
157. Pitson, S.M.; D'Andrea R, J.; Vandeleur, L.; Moretti, P.A.; Xia, P.; Gamble, J.R.; Vadas, M.A.; Wattenberg, B.W. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem. J., 2000, 350 Pt 2, 429-441.
158. Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; Chun, J. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 157-186.
159. Winter, J.N.; Fox, T.E.; Kester, M.; Jefferson, L.S.; Kimball, S.R. Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am. J. Physiol. Cell Physiol., 2010, 299(2), C335-344.
160. Leclercq, T.M.; Moretti, P.A.; Vadas, M.A.; Pitson, S.M. Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity. J Biol Chem, 2008, 283(15), 9606-9614.
161. Abbott, C.M.; Proud, C.G. Translation factors: in sickness and in health. Trends Biochem. Sci., 2004, 29(1), 25-31.
162. Ejiri, S. Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci. Biotechnol. Biochem., 2002, 66(1), 1-21.
163. Lamberti, A.; Caraglia, M.; Longo, O.; Marra, M.; Abbruzzese, A.; Arcari, P. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids, 2004, 26(4), 443-448.
164. Leclercq, T.M.; Moretti, P.A.; Pitson, S.M. Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene, 2011, 30(3), 372-378.
165. Mastrandrea, L.D.; Sessanna, S.M.; Laychock, S.G. Sphingosine kinase activity and sphingosine-1 phosphate production in rat pancreatic islets and INS-1 cells: response to cytokines. Diabetes, 2005, 54(5), 1429-1436.
166. Hait, N.C.; Sarkar, S.; Le Stunff, H.; Mikami, A.; Maceyka, M.; Milstien, S.; Spiegel, S. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J. Biol. Chem., 2005, 280(33), 29462-29469.
167. Olivera, A.; Urtz, N.; Mizugishi, K.; Yamashita, Y.; Gilfillan, A.M.; Furumoto, Y.; Gu, H.; Proia, R.L.; Baumruker, T.; Rivera, J. IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses. J. Biol. Chem., 2006, 281(5), 2515-2525.
168. Hait, N.C.; Bellamy, A.; Milstien, S.; Kordula, T.; Spiegel, S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J. Biol. Chem., 2007, 282(16), 12058-12065.
169. Ding, G.; Sonoda, H.; Yu, H.; Kajimoto, T.; Goparaju, S.K.; Jahangeer, S.; Okada, T.; Nakamura, S. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J. Biol. Chem., 2007, 282(37), 27493-27502.
170. Kohmura, K.; Miyakawa, Y.; Kawai, Y.; Ikeda, Y.; Kizaki, M. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. J. Cell Physiol., 2004, 198(3), 370-376.
171. Marley, S.B.; Lewis, J.L.; Schneider, H.; Rudd, C.E.; Gordon, M.Y. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br. J. Haematol., 2004, 125(4), 500-511.
172. Issuree, P.D.; Pushparaj, P.N.; Pervaiz, S.; Melendez, A.J. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J., 2009, 23(8), 2412-2424.
173. Kang, J.S.; Yoon, Y.D.; Han, M.H.; Han, S.B.; Lee, K.; Lee, K.H.; Park, S.K.; Kim, H.M. Glabridin suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking sphingosine kinase pathway: implications of Akt, extracellular signal-regulated kinase, and nuclear factor-kappaB/Rel signaling pathways. Mol. Pharmacol., 2006, 69(3), 941-949.
174. Silasi, D.A.; Alvero, A.B.; Rutherford, T.J.; Brown, D.; Mor, G. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin. Pharmacother., 2009, 10(6), 1059-1067.
175. Alvero, A.B.; Kelly, M.; Rossi, P.; Leiser, A.; Brown, D.; Rutherford, T.; Mor, G. Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol., 2008, 4(4), 475-482.
176. Gamble, J.R.; Xia, P.; Hahn, C.N.; Drew, J.J.; Drogemuller, C.J.; Brown, D.; Vadas, M.A. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int. J. Cancer, 2006, 118(10), 2412-2420.
177. De Luca, T.; Morre, D.M.; Zhao, H.; Morre, D.J. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors, 2005, 25(1-4), 43-60.
178. De Luca, T.; Bosneaga, E.; Morre, D.M.; Morre, D.J. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol. Biofactors, 2008, 34(3), 253-260.